CC-1088 Celgene.
作者信息
Dredge Keith
机构信息
Centre for Immunology and Cancer Research, Princess Alexandra Hospital, Woolloongabba, Brisbane, Queensland 4102, Australia.
出版信息
Curr Opin Investig Drugs. 2005 May;6(5):513-7.
PMID:15912966
Abstract
CC-1088, a thalidomide analog inhibitor of phosphodiesterase 4, was being developed by Celgene for the potential treatment of inflammatory diseases and myelodysplastic syndromes, and had undergone clinical trials. By April 2005, however, the company was no longer developing CC-1088, with CC-10004 presumed to be the preferred compound.
摘要
Zotero 插件